Topics

Roche's Tecentriq garners FDA approval for first-line use with chemotherapy in NSCLC https://www.firstwordpharma.com/node/1685238  $RHHBY

05:54 EST 4 Dec 2019 | FirstWord Pharma

Roche's Tecentriq garners FDA approval for first-line use with chemotherapy in NSCLC https://www.firstwordpharma.com/node/1685238 

Original Article: Roche's Tecentriq garners FDA approval for first-line use with chemotherapy in NSCLC https://www.firstwordpharma.com/node/1685238  $RHHBY

NEXT ARTICLE

More From BioPortfolio on "Roche's Tecentriq garners FDA approval for first-line use with chemotherapy in NSCLC https://www.firstwordpharma.com/node/1685238  $RHHBY"

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...